Evidence map›Paper›PMID 34442436›Full record

ArticleJournal of personalized medicine2021

Priscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso, José Luis Revuelta-Herrero, Fabienne Thomas, Sara López-Tarruella, Xandra García-González, Aitana Calvo, Malika Yakoubi, Sara Salvador-Martín and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Advances in laboratory medicine · 2025
    Article
  3. Article
  4. International journal of molecular sciences · 2024
    Article
  5. Clinical Implementation of Rare and NovelInternational journal of biological sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Priscila VillalvazoServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Belén Marzal-AlfaroServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Pilar García-AlfonsoServicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, 28007 Madrid, Spain.ORCID 0000-0002-4373-9978
José Luis Revuelta-HerreroServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0003-2071-8928
Fabienne ThomasDepartment of Pharmacology, Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, 20-24, 31300 Toulouse, France.
Sara López-TarruellaServicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, 28007 Madrid, Spain.
Xandra García-GonzálezServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0002-6269-7953
Aitana CalvoServicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, 28007 Madrid, Spain.
Malika YakoubiDepartment of Pharmacology, Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, 20-24, 31300 Toulouse, France.
Sara Salvador-MartínServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Flora López-LópezServicio de Oncología Médica, Fundación de Investigación Sanitaria Doce de Octubre, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain.
Iker AguilarServicio de Oncología Médica, Instituto de Investigación Sanitaria Ramón y Cajal, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
María Sanjurjo-SáezServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Miguel MartínServicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, 28007 Madrid, Spain.ORCID 0000-0001-9237-3231
Luis Andrés López-FernándezServicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.
Hospital General Universitario Gregorio Marañón · ESUniversidad Complutense de Madrid · ESUniversité Toulouse III - Paul Sabatier · FRHospital Universitario 12 De Octubre · ESInstituto Ramón y Cajal de Investigación Sanitaria · ES

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Instituto de Investigación Sanitaria Gregorio Marañón II-PI-2-2019NIGMS NIH HHS P41 GM103311
6 · The paper itself

Abstract

Dihydropyrimidine dehydrogenase deficiency is a major cause of severe fluoropyrimidine-induced toxicity and could lead to interruption of chemotherapy or life-threatening adverse reactions. This study aimed to characterize the

Indexed as

5-fluorouraciladverse drug eventscancercapecitabinepharmacogenetics

Identifiers

PMID34442436
PMCPMC8401253
OpenAlexW3194474699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.